MedPath

Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.

Phase 1
Completed
Conditions
HIV Infections
Registration Number
NCT00000818
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

PRIMARY: To determine the effect of 8 weeks of zidovudine (AZT) treatment on the HIV-1 burden in peripheral blood and lymphoid tissue in HIV-1-infected, AZT-naive patients with CD4+ T lymphocyte counts between 100 and 500 cells/mm3.

SECONDARY: To determine the extent to which apoptosis (programmed cell death) occurs in these patients.

In previous trials of AZT treatment in HIV-infected patients, an antiviral effect has been clearly demonstrated by quantitative measurement of virus in plasma and peripheral blood mononuclear cells. However, the lymphoid tissues appear to be a major reservoir for HIV-1 and a major site of virus replication in HIV-infected persons. Further data is needed to assess the effect of treatment on viral burden and HIV-1 replication in lymphoid tissue.

Detailed Description

In previous trials of AZT treatment in HIV-infected patients, an antiviral effect has been clearly demonstrated by quantitative measurement of virus in plasma and peripheral blood mononuclear cells. However, the lymphoid tissues appear to be a major reservoir for HIV-1 and a major site of virus replication in HIV-infected persons. Further data is needed to assess the effect of treatment on viral burden and HIV-1 replication in lymphoid tissue.

Patients receive AZT daily for 8 weeks and are followed in clinic at weeks 2, 4, 6, 8, 9, and 14 (or possibly via telephone call at week 14). Patients undergo a lymph node biopsy at day 0 and week 8.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

Univ of Texas Southwestern Med Ctr of Dallas

🇺🇸

Dallas, Texas, United States

Baylor College of Medicine / Houston Veterans Adm Med Ctr

🇺🇸

Houston, Texas, United States

Univ of Illinois

🇺🇸

Chicago, Illinois, United States

Mount Zion Med Ctr / UCSF

🇺🇸

San Francisco, California, United States

Cedars Sinai Med Ctr

🇺🇸

Los Angeles, California, United States

North Broward Hosp District

🇺🇸

Fort Lauderdale, Florida, United States

Goodgame Med Group

🇺🇸

Maitland, Florida, United States

Palo Alto Veterans Affairs Health Care System

🇺🇸

Palo Alto, California, United States

AIDS Community Research Consortium

🇺🇸

Redwood City, California, United States

© Copyright 2025. All Rights Reserved by MedPath